Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
Francis David Segal, a director of Ingevity Corp (NGVT), reported acquiring 414 vested deferred stock units on 10/01/2025 at a recorded price of $54.44 per share equivalent. These DSUs were elected in lieu of quarterly director fees and will convert into an equal number of common shares when Mr. Segal leaves board service under the company's Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this transaction, his reported beneficial ownership is 5,655 shares, held directly.
J. Kevin Willis, a director of Ingevity Corp (NGVT), reported a transaction dated 10/01/2025 in which he acquired 506 shares of Common Stock at a price of $54.44 per share. The Form 4 shows the shares represent vested deferred stock units that were elected in lieu of quarterly director fees and will convert into common shares upon his termination of board service under the company plans. After the reported transaction the filing shows the reporting person beneficially owned 8,300 shares directly. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Ingevity Corporation has agreed to sell substantially all assets of its industrial specialties product line (excluding lignin dispersant, alternative fatty acid based products, road technologies and certain other businesses) and its North Charleston, South Carolina crude tall oil refinery to Mainstream Pine Products, LLC under an Asset Purchase Agreement.
The Transaction provides for a purchase price of $110 million in cash, subject to customary working capital adjustments, plus up to an additional $19 million in contingent consideration based on the Businesses’ highest EBITDA over any 12‑month period within 36 months after closing. Closing is expected by early Q1 2026, subject to regulatory and contractual conditions, including absence of a Material Adverse Effect and completion of title and survey work.
The Agreement includes mutual termination rights, a $5 million termination fee for certain material breaches, a $7.5 million fee if Ingevity pursues an Alternative Transaction in violation of a “no shop” covenant, and a $520,000 diligence fee payable by Ingevity in most other termination scenarios. At closing, the parties plan to enter long‑term ground lease and reciprocal plant operating agreements (each with an initial 20‑year term and renewal options), transition services, intellectual property, restrictive covenant and environmental indemnity agreements that will govern ongoing collaboration around the refinery and nearby plant operations.
Phillip J. Platt, SVP, Finance & CAO of Ingevity Corp (NGVT), reported an equity transaction tied to vested restricted stock units. On 08/11/2025 the company withheld 1,444 shares to satisfy tax-withholding obligations related to 2024 RSUs that vested on that date. The transaction is coded F and shows a withholding value of $52.20 per share. After the withholding, Mr. Platt directly beneficially owned 28,243 shares.
This was a routine tax-withholding action for vested equity rather than an open-market sale; the form was submitted by one reporting person and executed under a power of attorney.
Ingevity Corporation (NGVT) Form 144 reports that insider Stuart E. Woodcock Jr. intends to sell 3,700 common shares on 08/11/2025 through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $194,662.55. The filing lists the securities as restricted stock that vested under a registered plan with acquisition dates of 02/27/2017, 02/27/2018 and 02/26/2020, and records a recent separate sale on 08/05/2025 of 6,720 shares for $323,904.00. Outstanding shares are shown as 36,466,285, so the planned sale represents a very small fraction of total common stock.
The notice includes the seller’s representation that they do not possess undisclosed material adverse information. The document otherwise provides routine Rule 144 disclosure details: broker, share counts, acquisition type, and prior recent sales by the same person.
Ingevity Corporation (NGVT) – Form 4 Insider Filing: Senior Vice President, General Counsel & Secretary Ryan C. Fisher reported a transaction dated 7 July 2025. The filing shows a Code F transaction in which 169 shares of common stock were withheld by the company at a price of $45.34 per share to cover tax obligations arising from the vesting of 2024 restricted stock units (RSUs). After the withholding, Fisher’s direct ownership stands at 14,758 NGVT shares. No derivative securities activity was reported, and there were no open-market purchases or sales.
Because Code F transactions are non-discretionary, cashless, and executed solely for tax-withholding, they typically carry limited market signaling value. The ownership reduction equals roughly -1.1% of Fisher’s previously held shares, a de-minimis change that is unlikely to materially affect investor perception of insider sentiment or the company’s share supply.